Görkem YILMAZ, EVRİM ERTEN, Nurhan FISTIKÇI, Şakire EREK, Ömer SAATÇİOĞLU

Addition of Lithium Therapy in a Patient with Persistent Neutropenia Triggered with Antipsychotics

Antipsikotik ilaçların kullanımı sırasında kan lökosit sayısında azalma görülebilmektedir. Bu tür durumlarda hastanın tedavisi kesilebilir ya da değiştirilebilir ve kan sayımı değerleri yakından izlenir. Ancak bu olgu sunumunda olduğu gibi tedavi değişikliklerinin kan tablosunda düzelmeyi sağlamadığı durumlarda, lityumla güçlendirme tedavisi düşünülmelidir. Bu olgu bildiriminin amacı, tipik ve atipik antipsikotik ilaçlara bağlı gelişen inatçı nötropeni olgularında tedaviye lityum eklenmesinin yararlı olabileceğine dikkat çekmektir

Antipsikotik kullanımıyla tetiklenen nötropeni olgusunda tedaviye lityum eklenmesi

Addition of lithium therapy in a patient with persistent neutropenia triggered with antipsychotics Decrease in leukocyte count might be seen during the use of antipsychotic medications. In such cases, treatment can be stopped or changed and blood count values must be closely monitored. As in this case report, however, if changing the treatment doesn’t provide improvement in blood counts, lithium augmentation can be considered. The objective of this case report is to point out that the addition of lithium therapy may be beneficial in patients with persistent neutropenia related to typical and atypical antipsychotic drugs

PDF

___

1. Cordes J, Streit M, Loeffler S, von Wilmsdorff M, Agelink M, Klimke A. Reversible neutropenia during treatment with olanzapine: three case reports. World J Biol Psychiatr 2004; 5:230-234.
2. Talarico L. Hematology consultation re: Leukopenia and neutropenia associated with the administration of Seroquel, Memorandum NDA 20-639. Department of Health and Human S, Public Health Services, Food and Drug Administration Center for Evaluation and Research, 1997.
3. Sluys M, Guzelcan Y, Casteelen G, de Haan L. Risperidoneinduced leucopenia and neutropenia: a case report. Eur Psychiatr 2004; 19:117.
4. Flanagan RJ, Dunk L. Haematological toxicity of drugs used in psychiatry. Hum Psychopharmacol Clin Exp 2008; 23:27-41.
5. Oluboka O, Haslam D, Lam T, Bown-Demarco D. Quetiapineinduced leucopenia: possible dosage-related phenomenon. Can J Psychiatry 2003; 48:65-66.
6. Shankar BR. Quetiapine-induced leucopenia and thrombocytopenia. Psychosomatics 2007; 48:530-531.
7. Ruhé HG, Becker HE, Jessurun P, Marees CH, Heeringa M, Vermeulen HD. Agranulocytosis and granulocytopenia associated with quetiapine. Acta Psychiatr Scand 2001; 104:311- 313.
8. Stergiou V, Bozikas VP, Garyfallos G, Nikolaidis N, Lavrentiadis G,Fokas K. Olanzapine-induced leucopenia and neutropenia. Prog Neuropsychopharmacol Biol Psychiatr 2005; 29:992-994.
9. Meylan C, Bondolfi G, Aubert AC, Baumann P. Reversible neutropenia during a cold: possible involvement of risperidone? A case report. Eur Neuropsychopharmacol 1995; 5:1-2.
10. Terao T, Oga T, Nozaki S, Ohta A, Ohtsubo Y, Yamamoto S, Zamami M, Okada M. Lithium addition to neuroleptic treatment in chronic schizophrenia: a randomized, double-blind, placebocontrolled, cross-over study. Acta Psychiatr Scand 1995; 92:220- 224.
11. Kanaan RA, Kerwin RW. Lithium and clozapine rechallenge: a retrospective case analysis. J Clin Psychiatry 2006; 67:756-760.
12. Pinninti NR, Houdart MP, Strouse EM. Case report of longterm lithium for treatment and prevention of clozapine-induced neutropenia in an African American male. J Clin Psychopharmacol 2010; 30:219-221.